We should be looking at overall mortality
Reduction of CV events and mortality is, of course, a great benefit.
However, what any patient would ask about a drug is 'Will it save my
life.' Not 'Will it make me less likely to die of a CV event, whilst at
the same time increasing my chance of dying of something else.'
I can't quite see the point of doing cost-effectiveness analysis
without taking into consideration the effect of treatment on overall
mortality. Which, in this case, was not done.
Competing interests: No competing interests